Roche integrates more than 20 advanced AI algorithms

Roche has extended its partnership with Exscientia to improve the efficiency of its end-to-end AI-driven drug discovery and development platform

Swiss pharmaceutical company Roche has extended its collaboration with artificial intelligence (AI)-driven drug discovery company Exscientia to integrate more than 20 advanced AI algorithms into its end-to-end AI-driven drug discovery and development platform.

New innovative medicines

The partnership aims to accelerate the generation of new and innovative medicines by leveraging Exscientia’s expertise in AI-powered drug design and Roche’s deep knowledge of biology and clinical development. The integration of Exscientia’s AI algorithms is expected to further enhance the efficiency and accuracy of Roche’s drug discovery process, leading to the identification and development of promising new therapies for patients.

Integrated and automated

Roche and Exscientia first began collaborating in 2019, and since then, the two companies have worked together to develop an integrated and automated drug discovery platform that leverages AI and machine learning to identify and optimise new drug candidates. The platform combines Exscientia’s AI-powered drug design capabilities with Roche’s expertise in biology, chemistry, and clinical development.

Successful partnership

The partnership has already yielded several successful projects, including the identification of potential new treatments for diseases such as cancer and neurodegenerative disorders. The expansion of the partnership and the integration of more advanced AI algorithms is expected to further accelerate the development of new and innovative medicines for patients.